Pharmaceutical company
- International corporate tax reform; Puerto Rico tax incentives - Issues related to Medicare Part B (Average Sales Price) and Part D (rebates) - Issues relating to the 340B Drug Pricing Program
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
STEVEN E IRIZARRY ISRAEL S KLEIN VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY ISRAEL S KLEIN VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY ISRAEL S KLEIN VINCENT A. ROBERTI, SR.